Who are Rhythm Pharmaceuticals, Inc.'s main suppliers?

Rhythm Pharmaceuticals, Inc. (RYTM) key suppliers include: CMOS, GENETIC-TESTING-SERVICE-PROVIDERS. View the full supplier network at chainsifter.com/chain/RYTM.

Who are Rhythm Pharmaceuticals, Inc.'s major customers?

Rhythm Pharmaceuticals, Inc. (RYTM) key customers include: SINGLE-CUSTOMER-IN-THE-UNITED-STATES, SINGLE-INTERNATIONAL-CUSTOMER, CMOS-POLYPEPTIDE-GROUP, ALEXION-PHARMACEUTICALS-INC. View the full customer network at chainsifter.com/chain/RYTM.

What sector is Rhythm Pharmaceuticals, Inc. in?

Rhythm Pharmaceuticals, Inc. (RYTM) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

RYTM Supply Chain: Rhythm Pharmaceuticals, Inc. Suppliers & Customers

2Suppliers

4Customers

2Debt Items

5Related Chains

Rhythm Pharmaceuticals, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CMOS	CMOS	85%	To meet our projected needs for clinical supplies to support our activities through regulatory approval and commercial manufacturing, the CMOs with whom we currently work may need to increase scale o…
GENETIC-TESTING-SERVICE-PROVIDERS	GENETIC-TESTING-SERVICE-PROVIDERS	85%	The Company relies on separate third parties to perform genetic testing in the United States and Europe, respectively.

Rhythm Pharmaceuticals, Inc. Customers

Ticker	Name	Confidence	Evidence
SINGLE-CUSTOMER-IN-THE-UNITED-STATES	SINGLE-CUSTOMER-IN-THE-UNITED-STATES	92%	For the three months ended March 31, 2026, and 2025, approximately 61 % and 65 % of all the Company’s revenue was generated from a single customer in the United States.
SINGLE-INTERNATIONAL-CUSTOMER	SINGLE-INTERNATIONAL-CUSTOMER	92%	Additionally, a single international customer also generated approximately 12 % of the Company's revenue during the three months ended March 31, 2026.
CMOS-POLYPEPTIDE-GROUP	CMOS-POLYPEPTIDE-GROUP	85%	in the future. We have entered into process development and manufacturing service agreements with our CMOs, PolyPeptide Group, Braine L'Alleud, or Polypeptide, Neuland Laboratories, and Astrea Monts …
ALEXION-PHARMACEUTICALS-INC	ALEXION-PHARMACEUTICALS-INC	62%	ial commercialization of a product candidate for CHI. In addition, since we have market access for IMCIVREE for BBS or POMC and LEPR deficiencies, or both, in more than 15 countries outside of the Un…

Rhythm Pharmaceuticals, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
RYTM-DEBT	Debt stack $112.3M	90%	Market cache reports total debt of $112.3M.
RYTM-DEBT-12337	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2025-12-31.

Rhythm Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Rhythm Pharmaceuticals, Inc..

Rhythm Pharmaceuticals, Inc. Ownership

Holder	Name	Confidence	Evidence
RYTM-OWNER-RA-CAPITAL-MANAGEMENT-L-P	RA CAPITAL MANAGEMENT, L.P.	90%	13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 288 tracked holders.

Rhythm Pharmaceuticals, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
BMRN	BioMarin Pharmaceutical Inc.	100.00	2
MYGN	Myriad Genetics, Inc.	100.00	2
SNYNF	Sanofi	100.00	2
CDMOS	CDMOS	50.00	2
PHVS	Pharvaris N.V.	36.29	1	['spend']

Rhythm Pharmaceuticals, Inc. Supply Chain